Hormone-Sensitive Prostate Cancer is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hormone-Sensitive Prostate Cancer have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hormone-Sensitive Prostate Cancer compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hormone-Sensitive Prostate Cancer overview
Hormone-sensitive prostate cancer (HSPC) is a type of prostate cancer that responds to hormone therapy, which aims to reduce or block the production or action of androgens such as testosterone. Androgens are male sex hormones that stimulate the growth of normal and cancerous prostate cells. Most prostate cancers are initially hormone-sensitive, but they may become castration-resistant over time, meaning that they continue to grow despite low or undetectable levels of androgens. Hormone therapy for HSPC can slow down the progression of the disease and improve survival outcomes. However, hormone therapy can also cause side effects such as hot flashes, sexual dysfunction, bone loss, fatigue, and mood changes. Therefore, patients with HSPC should discuss the benefits and risks of hormone therapy with their doctors and consider their quality of life and personal preferences when choosing a treatment option.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Hormone-Sensitive Prostate Cancer, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
